Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Hoge dosis ambroxol bij GBA1-gerelateerde Parkinson

4 november 2026 bijgewerkt door: Agyany Pharma LTD

Een open-label pilotstudie voor het beoordelen van de veiligheid en werkzaamheid van hoge doses ambroxol (HDA) bij nieuw gediagnosticeerde GBA1-gerelateerde motorische en premotorische ziekte van Parkinson (PD)

Parkinson's disease (PD), affecting 10 million people globally, lacks a cure, and current therapies only manage symptoms. A link between Gaucher disease (GD) and PD, particularly in carriers of glucocerebrosidase (GBA1) mutations, has sparked interest in developing new drugs. Despite pharmaceutical companies focusing on formulations, progress is slow. Agyany, with decades of experience in GD research, plans clinical trials using existing generic drugs for GBA-related PD and idiopathic PD. Their approach targets the misfolded enzyme glucocerebrosidase with pharmacological chaperons, inspired by success in GD using ambroxol. The strategy aims to provide a quicker path to novel therapeutic options for PD.

Studie Overzicht

Toestand

Beëindigd

Interventie / Behandeling

Gedetailleerde beschrijving

Parkinson disease (PD) is the second most common neurodegenerative disease affecting around 10 million people worldwide. It is a debilitating disorder that despite many years and billions of dollars research - there is still no cure and none of the therapeutic options truly reverse its manifestations. The realization that the relationship between Gaucher disease (GD) - the rare lysosomal storage disease - and PD, also exists in carriers of the disease (with a mono-allele mutation in glucocerebrosidase (GBA1)) has led to several attempts to develop new drugs not just for GBA-related PD, but also for PD at large. However, heretofore all pharmaceutical companies have focused on finding new formulations, mostly based on what Agyany believe is not targeting the underlying pathology, but in any case, will require several years before new drugs will reach the market. With the background of three decades working at the world's largest center for GD at Shaare Zedek Medical Center in Jerusalem, and with a different understanding of the pathological processes leading to PD among a significant number of GD patients and carriers, Agyany plans to begin clinical trials in newly diagnosed PD patients using existing generic drugs that would enable a short path for introducing novel therapeutic approach to GBA-related PD and potentially also for so called idiopathic PD (when no genetic cause is known).

Based on our understanding of the underlying mechanism of GBA1-related PD, on research done in animal models and on our own anecdotal experience, Agyany believe that pharmacological chaperons are the most reasonable therapeutic modality to achieve success. Since the misfolding of the mutant enzyme, glucocerebrosidase, is the same both in GBA1-related PD and GD, and that the ambroxol impact is the same as well, Agyany can extrapolate from the success of ambroxol to achieve reversibility of neuronopathic features (that heretofore were considered irreversible, and the best expectation was lack of deterioration), in neuronopathic GD (nGD), to potential success in GBA-related PD.

The plan is to first use generic formulations with a confirmed safety profile and repurpose their indication to PD.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

46

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Jerusalem, Israël, 9103102
        • Shaare Zedek Medical Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

30 jaar tot 70 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

For inclusion into the trial, subjects are required to fulfill all of the following criteria:

Newly diagnosed PD patients:

  1. Individuals who exclusively carry at least one single GBA1 variant without any additional genetic variants.

  2. Confirmed diagnosis of PD, by a movement disorder specialist, according to MDS PD criteria, within a maximum of three years from the date of diagnosis, coupled with the following conditions:

    iii. Hoehn and Yahr staged between I-II, inclusive.

    iv. No motor fluctuations or L-dopa induced dyskinesia.

  3. Stable anti-PD medications for ≥ 4 weeks:

    Subjects can take PD medications including NMDA glutamate antagonists, monoamine oxidase B (MAO-B) inhibitors, dopamine agonists, and L-Dopa.

  4. Male or female, age 30-70 years; however, if female:

    • must be using contraception measures if of childbearing potential.
    • must not be lactating.
  5. Complying with study protocol.

Exclusion Criteria:

Eligible subjects may not have any of the following exclusion criteria:

  1. Presence of any medical, emotional, behavioral, or psychological condition that in the judgment of the Investigator would interfere with the subject's compliance with the requirements of the study (such as clinical depression).

  2. Any other disorder that may interfere with the results of the efficacy endpoints.

  3. Currently taking another investigational drug for any condition.

  4. Use of dopaminergic treatment under these conditions:

    • L-Dopa equivalent daily dose > 400mg
    • L-Dopa daily dose > 300mg
    • L-Dopa equivalent and L-Dopa daily dose has been changed in the past 4 weeks prior to screening visit.
  5. Medical history of psychosis.

  6. Exposure to ambroxol in the last 24 months prior to screening and/or history of adverse events to ambroxol.

  7. Exposure to dopamine receptor blocking agents, lithium, cinnarizine, amiodarone or valproic acid in the last 12 months prior to screening.

  8. Pregnancy or lactation; female subjects of a childbearing age who are unwilling to use contraceptive measures.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Ambroxol hydrochloride

Daily administration of Ambroxol in newly diagnosed GBA1 PD.

75mg slow release (SR), X16/day or 300mg X4/day oral capsules.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)
Tijdsspanne: 12 months

The outcome measure involves the assessment of adverse events (AEs) experienced by study participants throughout the duration of the trial. Adverse events will be documented, and their severity will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5. This comprehensive evaluation aims to provide a clear understanding of the safety profile of the intervention by specifically measuring and reporting the incidence and severity of treatment-emergent adverse events.

12 months
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematology
Tijdsspanne: 12 months

Criteria for potentially clinically significant abnormalities (PCSA): Hemoglobin: less than or equal to (<=) 115 grams per liter (g/L) (Male[M]) or <=95 g/L (Female[F]), greater than or equal to (>=) 185 g/L (M) or >=165 g/L (F), Decrease from baseline (DFB) >=20 g/L; Hematocrit: <=0.37 volume/volume (v/v) (M) or <=0.32 v/v (F), >=0.55 v/v (M) or >=0.5 v/v (F); Red blood cells (RBC): >=6 Tera/L; Platelets: less than (<) 100 Giga/L, >=700 Giga/L; White blood cells (WBC): <3.0 Giga/L (Non-Black [NB]) or <2.0 Giga/L (Black [B]), >=16.0 Giga/L; Neutrophils: <1.5 Giga/L (NB) or <1.0 Giga/L (B); Lymphocytes: <lower limit of normal (LLN), greater than (>) 4.0 Giga/L; Monocytes: <LLN, >0.7 Giga/L; Basophils: >0.1 Giga/L; Eosinophils: >0.5 Giga/L or >upper limit of normal (ULN) (if ULN >=0.5 Giga/L).

12 months
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Biochemistry (Metabolic, Electrolytes, Renal and Liver Function)
Tijdsspanne: 12 months

Criteria for PCSA: Alanine Aminotransferase (ALT): >3 ULN, >5 ULN; Aspartate aminotransferase (AST): >3 ULN; Alkaline phosphatase: >1.5 ULN; Total Bilirubin: >1.5 ULN; ALT and Bilirubin: >3 ULN and >2 ULN; Direct Bilirubin and Bilirubin: >35% and >1.5 ULN.

Criteria for PCSA: Creatinine: >=150 micromoles per liter (mcmol/L) (adults), >=30% change from baseline, >=100% change from baseline; Blood urea nitrogen: >=17 millimoles (mmol)/L.

Criteria for PCSA: Glucose: <=3.9 mmol/L and <LLN; >=11.1 mmol/L (unfasted [unfas]) or >=7 mmol/L (fasted [fas]); Albumin: <=25 g/L.

Criteria for PCSA: Sodium: <=129 mmol/L, >=160 mmol/L; Potassium: <3 mmol/L, >=5.5 mmol/L and Chloride: <80 mmol/L, >115 mmol/L.

12 months
Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
Tijdsspanne: 12 months

Criteria for PCSA: Systolic blood pressure (SBP) supine: <=95 millimeters of mercury (mmHg) and DFB >=20 mmHg; >=160 mmHg and increase from baseline (IFB) >=20 mmHg; Diastolic blood pressure (DBP) supine: <=45 mmHg and DFB >=10 mmHg; >=110 mmHg and IFB >=10 mmHg; SBP (Orthostatic): <=-20 mmHg; DBP (Orthostatic): <=-10 mmHg; Heart rate (HR) supine: <=50 beats per minute (bpm) and DFB >=20 bpm; >=120 bpm and IFB >=20 bpm; Weight: >=5% DFB; >=5% IFB.

12 months
Number of Participants With Abnormal Physical Examination Findings
Tijdsspanne: 12 months

Routine physical examinations will be conducted to assess participants for any physical manifestations of adverse effects or safety concerns.

In the final report the number of participants with new abnormal physical examination findings will be reported.

12 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Participants With Significant Change in Transcranial Ultrasonography (TCS) of Substantia Nigra Region
Tijdsspanne: 12 months

Transcranial Ultrasonography detects the area of hyper-echogenicity in the region of substantia nigra (values greater than 0.2 cm square are considered abnormal.

Improvement from baseline will be assessed and considered significant if greater than 15% from baseline.

12 months
Difference of dopamine turnover rate measured by Fluoro-Dopa-PET in the putamen between baseline and after 12 months of treatment.
Tijdsspanne: 12 months

Change from baseline to end of study (EOS) in F-DOPA imaging will be qualitative as assessed by independent expert in nuclear medicine in a central imaging center.

12 months

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Changes in motor evaluations
Tijdsspanne: 12 months

Using: (Video-recorded unified Parkinson's disease rating scale (MDS-UPDRS) Part II and III.

12 months
Changes in motor evaluations
Tijdsspanne: 12 months

Perdue pegboard

12 months
Changes in motor evaluations
Tijdsspanne: 12 months

Trail Making Test (TMT)

12 months
Change in cognitive and mental impairment
Tijdsspanne: 12 months

Montreal Cognitive Assessment (MoCa)

12 months
Change in cognitive and mental impairment
Tijdsspanne: 12 months

NeuroTrax

12 months
Change in cognitive and mental impairment
Tijdsspanne: 12 months

Clinical Global Impression Scale (CGI)

12 months
Change in cognitive and mental impairment
Tijdsspanne: 12 months

Hooper Visual Organization Test (VOT)

12 months
Change in cognitive and mental impairment
Tijdsspanne: 12 months

Beck Depression inventory (BDI)

12 months
Change in sleep behavior
Tijdsspanne: 12 months

REM sleep behavior disorder (RBD)

12 months
Change in sleep behavior
Tijdsspanne: 12 months

Epworth sleepiness scale (ESS)

12 months
Changes in sensory and autonomic assessments
Tijdsspanne: 12 months

Using the following tests: the BIT University of Pennsylvania brief Smell Identification Test (UPSIT)

12 months
Changes in sensory and autonomic assessments
Tijdsspanne: 12 months

Constipation questionnaire

12 months
Changes in sensory and autonomic assessments
Tijdsspanne: 12 months

Orthostatic hypotension (OH)

12 months
Changes in sensory and autonomic assessments
Tijdsspanne: 12 months

Color discrimination.

12 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie stoel: Ari Zimran, MD, Agyany Pharma LTD

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

24 oktober 2023

Primaire voltooiing (Werkelijk)

30 maart 2026

Studie voltooiing (Werkelijk)

30 april 2026

Studieregistratiedata

Eerst ingediend

7 november 2023

Eerst ingediend dat voldeed aan de QC-criteria

4 januari 2024

Eerst geplaatst (Werkelijk)

5 januari 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

9 november 2026

Laatste update ingediend die voldeed aan QC-criteria

4 november 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

There is no plan to share such data.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren